Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I. Florou V, et al. Among authors: maoz a. J Immunother Cancer. 2023 Aug;11(8):e007440. doi: 10.1136/jitc-2023-007440. J Immunother Cancer. 2023. PMID: 37586768 Free PMC article.
T-Cell Transfer Therapy Targeting Mutant KRAS.
Maoz A, Rennert G, Gruber SB. Maoz A, et al. N Engl J Med. 2017 Feb 16;376(7):e11. doi: 10.1056/NEJMc1616637. N Engl J Med. 2017. PMID: 28207209 Free PMC article. No abstract available.
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.
Naqash AR, Floudas CS, Aber E, Maoz A, Nassar AH, Adib E, Choucair K, Xiu J, Baca Y, Ricciuti B, Alessi JV, Awad MM, Kim C, Judd J, Raez LE, Lopes G, Nieva JJ, Borghaei H, Takebe N, Ma PC, Halmos B, Kwiatkowski DJ, Liu SV, Mamdani H. Naqash AR, et al. Among authors: maoz a. JCO Precis Oncol. 2024 Feb;8:e2300371. doi: 10.1200/PO.23.00371. JCO Precis Oncol. 2024. PMID: 38330261
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, Yang D, Phan N, Bell GW, Hata AN, Weiskopf K. Vaccaro K, et al. Among authors: maoz a. bioRxiv [Preprint]. 2023 Mar 6:2023.03.03.531059. doi: 10.1101/2023.03.03.531059. bioRxiv. 2023. Update in: J Clin Invest. 2024 Mar 14;134(9):e169315. doi: 10.1172/JCI169315. PMID: 36945559 Free PMC article. Updated. Preprint.
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN, Neuhausen SL, Adamson A, Tao S, Ricker C, Maoz A, Rosenblatt M, Nehoray B, Sand S, Steele L, Unzeitig G, Feldman N, Blanco AM, Hu D, Huntsman S, Castillo D, Haiman C, Slavin T, Ziv E. Weitzel JN, et al. Among authors: maoz a. Cancer. 2019 Aug 15;125(16):2829-2836. doi: 10.1002/cncr.32083. Epub 2019 Jun 17. Cancer. 2019. PMID: 31206626 Free PMC article.
Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R, Melas M, Maoz A, Schmit SL, Rennert H, Lejbkowicz F, Greenson JK, Sanjuan X, Lopez-Zambrano M, Alonso MH, Qu C, McDonnell KJ, Idos GE, Vignali M, Emerson R, Fields P, Guinó E, Santos C, Salazar R, Robins HS, Rennert G, Gruber SB, Moreno V. Sanz-Pamplona R, et al. Among authors: maoz a. PLoS Med. 2020 Sep 24;17(9):e1003292. doi: 10.1371/journal.pmed.1003292. eCollection 2020 Sep. PLoS Med. 2020. PMID: 32970670 Free PMC article.
48 results